Capsid and Tail

a weekly phage periodical
Issue 17: Incentives for phage drug development
February 15, 2019

Incentives for phage drug development

A look into government incentives for antimicrobial development, and how they apply to phage therapeutic development.

In addition to patents and trade secrets, which we discussed in previous issues (see part I here, part II here, and part III here), there are other ways of encouraging and protecting investment into phage therapeutics. This week, we’ll discuss government incentives as they relate to antimicrobial/phage development.

What's New

Cell Host & Microbe just released a special issue devoted to phages!. This includes four free featured reviews, one of which is this article by Kaitlyn Kortright, Benjamin Chan, Jonathan Koff and Paul Turner of Yale University, where they describe the use of phages to select against virulence and antibiotic resistance. Excitingly, they also take us through five clinical case studies and the three most advanced phage clinical trials done to date.

Phage TherapyReviewSpecial Issue

Fernando L. Gordillo Altamirano and Jeremy Barr from Monash University in Melbourne, Australia have published a new review: Phage Therapy in the Post-Antibiotic Era. Their paper includes a nice timeline of phage therapy history and a beautiful figure depicting modern approaches to phage therapy (including immuno-phage-antibiotic synergy, engineered phages, and lysins in addition to conventional phage therapy).

Phage TherapyReview

Stephen Wandro and colleagues at the University of California, Irvine have published a new paper on Enterococcus faecium phage evolution. His experiments, which he presented at Kisaco Research’s North American Microbiome Congress last week, allowed him to clearly track phage and host resistance coevolution, and would be useful for others to do on their phages!

ResearchUseful method

Intralytix’s phage clinical trial (treating E. coli in IBD patients) at Mt. Sinai hospital has begun! Here’s a video interview with two Mt. Sinai doctors involved in the trial

VideoInterviewClinical TrialsIBD

Phages for Global Health has announced a call for applications for its first West Africa Phage Workshop, which will take place July 7 - 20, 2019, at Kwame Nkrumah University of Science and Technology in Ghana. Apply now!

AnnouncementWorkshop

Latest Jobs

Programmer position: viral bioinformatics
Center for Phage Technology, Texas A&M University, College Station, TX

The Center for Phage Technology is looking for a Programmer I, which will, under direction, perform specialized software development and support functions such as troubleshooting, debugging, problem-solving, analysis, and research in a viral bioinformatics field.

Programmer VirologySoftware Development
Postdoctoral position: insect virus diversity
Viroplant H2020, Montpellier, France
Dr. Mylene Ogliastro

Looking for motivated postdoc who wants to explore virus diversity (in insects). This is part of an EU project, ViroplantH2020, and is a 2-year position. Experience in viral metagenomics and bionformatics required. Position available now in Montpellier, France. Contact @MOgliastro for details.

Post Doc VirologyMetagenomicsBioinformatics

Community Board

Have a question or request for the phage community? Post it here and reach > 300 phage enthusiasts spanning academia, industry, medicine, and beyond. Feel free to be creative about what you might ask! (e.g. collaborations, advice, seeking opportunities). Find the week’s new requests here in Capsid & Tail, or find a list of all active requests here.

The community board is empty this week. Be the first to post something for next week!

Incentives for phage drug development

If phage therapeutics are going to be developed as drugs, at least in the US, there needs to be significantly more investment into their development. With the patentability of phages in question, companies may need to find alternative ways of encouraging and protecting investment into phage therapeutics.

We’ve talked about trade secrecy, which can help, but we haven’t yet talked about the important role government incentives can play in incentivizing drug development, especially drugs related to combating antimicrobial resistance. As phages are becoming more recognized as a part of this category, drug companies seeking to commercialize phages should be on the lookout for government funding opportunities they could be eligible for.

Two main kinds of antimicrobial drug development incentives:

  1. Push incentives: e.g. government provides funds to help get a drug to market. This can be at the level of basic research, preclinical and/or clinical development; essentially, anytime BEFORE the drug makes it to market. Main sources in the US: NIAID and BARDA (which has led to CARB-X, a private-public partnership to accelerate efforts to combat antibiotic resistance).

  2. Pull incentives: e.g. government provides funds as a “reward” for bringing a drug to market. This can help de-link how much money a drug brings in from how much money the drug company makes off of it. This could be especially important for phage-based therapeutics, which could provide a high societal value without necessarily commanding a high revenue. Pull incentives appear to be less common than push incentives, but are being called for in the US (see this recent letter to the US Senate, which was signed by many biotech and pharma companies). The UK recently announced a national plan for combating antibiotic resistance that includes pull incentives for antimicrobial development, which is a good sign that more governments could
    follow suit—see this blog post to learn more
    .

Beyond grant funding

In addition to grant/prize money, some new models for antimicrobial development-related government incentives that have been proposed include:

  • Setting up tax credits for drug manufacturers,
  • Extending medicare coverage for certain drugs to help ensure drugs will be reimbursed properly (a drug on the market that is not actually prescribed by physicians or not covered by insurance policies may not make money, even if it works),
  • Issuing patent-extending vouchers to companies that take a drug to market, which could be sold to larger companies that have their own patents.

At this point, although bills to pass such policies for antimicrobial development have made it to US congress, they seem to have since died. However, times are changing, and this should be an interesting area to watch going forward.

Where do phage therapeutics fit in?

Most discussion of these kinds of incentives has centered around new antibiotic development. However, certain existing programs for combating antimicrobial resistance have funded phage development, and now even name phage (and phage-derived) therapeutic product development when listing what they will fund, which is encouraging.

For example, NIAID has already funded at least seven phage projects (page 803) in response to President Obama’s National Action Plan for Combating Antibiotic-Resistant Bacteria. Additionally, CARB-X, which is jointly funded by BARDA and the Wellcome Trust, recently announced its funding of the phage lysin company ContraFect.

What can you do with this information?

One thing you can do now is take a look at the request NIAID just issued for comments and suggestions on its Antibacterial Resistance Research Framework. In 2014, NIAID laid out 7 approaches for tackling AMR (including exploring phage therapy), and they’re updating these approaches this year. You can submit comments & suggestions here. Deadline: Mar. 8, 2019.

If you’re interested in learning more or following new updates in antimicrobial drug development policy, you can also subscribe to the blog/newsletter of Dr. John Rex, MD at the Wellcome Trust. This was a major source for this issue (thanks Tobi Nagel for the suggestion!).

Thanks for reading this multi-part series, where we covered patents, phage patentability, trade secrecy and, lastly, government incentives, as they apply to phage development.

What we’ve gone over here only scratches the surface when it comes to all the possible legal and government policy-level solutions that could be enacted to help encourage companies to bring phage therapeutics to market. We hope we’ve at least given you a taste of the possibilities that exist!

Thanks for reading!
– Jessica <>={

Main sources:

Kelly Todd. The Promising Viral Threat to Bacterial Resistance: The Uncertain Patentability of Phage Therapeutics and the Necessity of Alternative Incentives, 68 Duke Law Journal 767-805 (2019)
Available at: https://scholarship.law.duke.edu/dlj/vol68/iss4/3

John H. Rex. Solutions for Antimicrobial Resistance. Available at: http://amr.solutions/blog.html

Jessica Sacher is a co-founder of Phage Directory and has a Ph.D in Microbiology and Biotechnology

For every issue of Capsid & Tail, we are committed to getting our facts straight, but we’re not experts in the information we’re bringing to you. If you feel that we’ve missed an important viewpoint, or if you have something to add, please reach out to us by emailing [email protected]. We’d love to hear from you, and we’d be happy to revisit topics we’ve covered (ideally with added information and viewpoints from community members like you!).

Lastly, please reach out if you’re interested in writing for us, or have suggestions for future issues!